Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Fatigue and ESR1[original query] |
---|
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. The Lancet. Oncology 2020 9 21 (10): 1296-1308. Turner Nicholas C, Kingston Belinda, Kilburn Lucy S, Kernaghan Sarah, Wardley Andrew M, Macpherson Iain R, Baird Richard D, Roylance Rebecca, Stephens Peter, Oikonomidou Olga, Braybrooke Jeremy P, Tuthill Mark, Abraham Jacinta, Winter Matthew C, Bye Hannah, Hubank Michael, Gevensleben Heidrun, Cutts Ros, Snowdon Claire, Rea Daniel, Cameron David, Shaaban Abeer, Randle Katrina, Martin Sue, Wilkinson Katie, Moretti Laura, Bliss Judith M, Ring Alista |
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR?+?/HER2?-) advanced/metastatic breast cancer. Breast cancer research and treatment 2022 11 197 (2): 319-331. Bardia Aditya, Mayer Ingrid, Winer Eric, Linden Hannah M, Ma Cynthia X, Parker Barbara A, Bellet Meritxell, Arteaga Carlos L, Cheeti Sravanthi, Gates Mary, Chang Ching-Wei, Fredrickson Jill, Spoerke Jill M, Moore Heather M, Giltnane Jennifer, Friedman Lori S, Chow Maneval Edna, Chan Iris, Jhaveri Kom |
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. The Lancet. Oncology 2022 10 23 (11): 1367-1377. Bidard François-Clément, Hardy-Bessard Anne-Claire, Dalenc Florence, Bachelot Thomas, Pierga Jean-Yves, de la Motte Rouge Thibault, Sabatier Renaud, Dubot Coraline, Frenel Jean-Sébastien, Ferrero Jean Marc, Ladoire Sylvain, Levy Christelle, Mouret-Reynier Marie-Ange, Lortholary Alain, Grenier Julien, Chakiba Camille, Stefani Laetitia, Plaza Jérôme Edouard, Clatot Florian, Teixeira Luis, D'Hondt Véronique, Vegas Hélène, Derbel Olfa, Garnier-Tixidre Claire, Canon Jean-Luc, Pistilli Barbara, André Fabrice, Arnould Laurent, Pradines Anne, Bièche Ivan, Callens Céline, Lemonnier Jérôme, Berger Frédérique, Delaloge Suzette, |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: